皮肤病血毒片联合多西环素治疗痤疮的临床研究

目的探讨皮肤病血毒片联合盐酸多西环素分散片治疗痤疮的临床疗效。方法选取2017年2月—2017年7月在监利县人民医院进行诊治的痤疮患者78例临床资料进行回顾性分析,根据用药的不同将所有患者分为对照组和治疗组,每组各39例。对照组口服盐酸多西环素分散片,1片/次,2次/d。治疗组在对照组基础上口服皮肤病血毒片,6片/次,2次/d。两组均连续治疗8周。观察两组的临床疗效,比较两组的红斑评分、色素沉着评分、皮损数量评分、痤疮特异性生活质量量表(Acne-QOL)评分、血清学指标。结果治疗后,对照组和治疗组的总有效率分别为79.49%、94.87%,两组比较差异具有统计学意义(P0.05)。治疗后,两组红斑、色素沉着、皮损数量评分显著下降,Acne-QOL评分显著上升,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组这些评分指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组血清肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)、白细胞介素-17(IL-17)水平明显降低,白细胞介素-10(IL-10)、干扰素-γ(IFN-γ)水平明显升高,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组这些血清学指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。结论皮肤病血毒片联合盐酸多西环素分散片治疗痤疮具有较好的临床疗效,可促进皮肤红斑和色素沉着消退,改善皮损,调节机体炎症反应,提高生活质量,具有一定的临床推广应用价值。     

复方黄柏液联合夫西地酸乳膏治疗寻常痤疮的疗效观察

目的探究应用复方黄柏液联合夫西地酸乳膏治疗寻常痤疮的临床疗效和价值。方法选取本院2012年10月—2013年9月收治的寻常痤疮患者231例,将患者随机分为治疗组（120例）和对照组（111例）,治疗组应用复方黄柏液湿敷联合夫西地酸乳膏外涂治疗,对照组单纯应用夫西地酸乳膏外涂治疗。治疗结束后比较两组患者治疗效果。结果治疗组治疗总有效率为95.0%（114/120）,高于对照组的79.3%（88/120）,差异有统计学意义（P〈0.05）。结论应用复方黄柏液联合夫西地酸乳膏治疗寻常痤疮,疗效确切,安全高效。     

百癣夏塔热片治疗寻常痤疮的临床观察

目的：探讨百癣夏塔热片在治疗寻常痤疮中的临床应用价值。方法：将126例寻常痤疮患者随机分成两组，每组63例，分别给予百癣夏塔热片和四环素进行对照治疗，每周记录1次皮损变化，对比观察治疗前、后痤疮皮损减少率。结果：治疗组总有效率79．37％；对照组总有效率68．26％，两组间差异有统计学意义（P〈0．05）。结论：百癣夏塔热片口服对寻常痤疮是安全、有效的治疗方法，值得临床推广。     

百癣夏塔热片联合多西环素治疗寻常性痤疮的临床疗效观察

目的：探讨临床上应用百癣夏塔热片联合多西环素对于寻常性痤疮的治疗效果。方法：选取2014年12月～2015年12月于我院接受治疗的寻常性痤疮患者共计86例,随机分为对照组及观察组,每组43例。对照组患者单纯给予多西环素对寻常性痤疮进行治疗,而观察组患者给予多西环素的同时给予百癣夏塔热片进行治疗。对比两组患者的临床治疗效果及不良反应的发生率。结果：两组患者均完成相应治疗,与对照组患者寻常性痤疮的治疗率（76.74%）比较,观察组患者治疗率为93.02%,两组患者治疗率具有显著性差异（P＜0.05）。两组患者治疗期间均出现轻微不良反应症状,给药结束后自动恢复正常。观察组患者治疗期间不良反应的发生率为4.65%,与对照组患者（不良反应发生率为6.97%）相比无统计学差异（P＞0.05）。结论：临床对于寻常性痤疮患者的治疗,应用百癣夏塔热片联合多西环素比单纯应用多西环素治疗疗效更为显著,且安全性较高,值得临床推广应用。     

润燥止痒胶囊联合他扎罗汀乳膏治疗寻常型痤疮的临床研究

目的探讨润燥止痒胶囊联合他扎罗汀乳膏治疗寻常型痤疮的临床疗效。方法选取2017年3月—2018年3月在海南省皮肤病医院进行诊治的84例寻常型痤疮患者为研究对象,根据用药的差别将所有患者分为对照组和治疗组,每组各42例。对照组将面部清洁干燥后,取2 mg/cm2他扎罗汀乳膏均匀涂于患处,每晚用药一次;治疗组在对照组基础上口服润燥止痒胶囊,2 g/次,3次/d。两组患者均治疗8周。观察两组患者临床疗效,比较治疗前后两组患者的相关评分及炎症指标。结果治疗后,对照组和治疗组临床总有效率分别为80.95%、97.62%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者红斑、色素沉着、银屑病皮损面积和严重程度指数(PASI)、皮肤病生活质量指数(DLQI)评分显著降低,同组治疗前后比较差异具有统计学意义(P0.05);且治疗后治疗组患者上述评分显著低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组血清肿瘤坏死因子(TNF-α)、白细胞介素-4(IL-4)、白细胞介素-17(IL-17)、可溶性白细胞介素-2受体(SIL-2R)水平均显著降低,同组治疗前后比较差异具有统计学意义(P0.05);且治疗后治疗组炎症指标水平明显低于对照组,两组比较差异具有统计学意义(P0.05)。结论润燥止痒胶囊联合他扎罗汀乳膏治疗寻常型痤疮可有效促进皮肤红斑及色素沉着消退,提高生活质量,改善机体炎症反应,具有一定的临床推广应用价值。     

百癣夏塔热辅助治疗寻常痤疮的临床疗效及对炎症因子影响

目的 研究百癣夏塔热辅助治疗寻常痤疮的临床疗效及对炎症因子影响。 方法 选取河北省保定市第五医院2015年6月到2016年8月间收治的寻常痤疮患者86例,采用随机数字法将其分为对照组和观察组,每组各43例。对照组患者接受红蓝光交替照射治疗联合异维A酸红霉素凝胶外敷治疗,于每晚敷用,在此基础上,观察组患者口服百癣夏塔热,3次/天,1.2 克/次。均连续治疗8周。比较两组患者的治疗疗效和不良反应发生率,同时比较治疗前后的血清IL-6、IL-8及TNF-α水平。 结果 观察组的治疗总有效率(88.37%)明显高于对照组(69.77%)(χ²=4.50,P=0.03);治疗后,观察组的血清IL-6、IL-8及TNF-α水平均明显低于对照组(P<0.01);两组患者的不良反应发生率比较差异无统计学意义 (P>0.05)。 结论 百癣夏塔热能提高寻常痤疮的治疗疗效,并能改善患者的免疫功能,且治疗安全性较高,是一种高效的治疗方法,值得在临床推广。     

夫西地酸乳膏联合丹参酮胶囊治疗痤疮临床观察

目的探讨夫西地酸乳膏联合丹参酮胶囊治疗痤疮的临床疗效。方法选取北京市延庆区医院2014年6月～2015年6月诊治的痤疮患者162例,采用随机数字表法分为两组,对照组患者81例采用罗红霉素分散片联合夫西地酸乳膏治疗,观察组患者81例采用丹参酮胶囊联合夫西地酸乳膏治疗,于治疗前后行痤疮GAGS评分,记录两组患者的治疗情况(起效时间、复发时间),比较两组患者的临床疗效(治愈、显效、好转、无效、总有效)、药物不良反应情况(口唇干燥、轻度脱屑、胃部不适、皮疹反应)。结果两组患者治疗后痤疮GAGS评分较治疗前降低。观察组患者治疗后痤疮GAGS评分[(8.7±1.0)分]低于对照组[(13.4±1.5)分]。观察组患者起效时间[(4.3±1.2)d]早于对照组[(5.6±1.8)d]。观察组患者复发时间[(31.2±1.4)d]晚于对照组[(24.6±2.7)d]。观察组患者总有效率(98.8%)高于对照组(88.9%)。观察组患者药物不良反应发生率(3.7%)低于对照组(14.8%),差异均有统计学意义(P 0.05)。结论夫西地酸乳膏联合丹参酮胶囊治疗痤疮的疗效显著,且安全性高,值得临床推广使用。     

替硝唑螺内酯乳膏治疗寻常痤疮62例

目的观察替硝唑螺内酯乳膏治疗寻常痤疮的临床疗效。方法将寻常痤疮患者94例分为两组,其中治疗组62例予替硝唑螺内酯乳膏,对照组32例予夫西地酸乳膏,局部外搽,每日2次,4周为1个疗程。结果治疗组总有效率91.94%,总显效率85.48%;对照组总有效率75.00%,总显效率37.50%。经统计学处理,治疗组疗效明显优于对照组（P〈0.05）。结论替硝唑螺内酯乳膏治疗寻常痤疮疗效确切,对痤疮患者炎症性皮损如丘疹、脓疱的消除尤为有效。     

异维A酸胶丸联合百癣夏塔热片治疗中重度寻常型痤疮临床疗效观察

目的：探讨异维A酸胶丸联合百癣夏塔热片治疗中重度寻常型痤疮的临床效果。方法：采用随机、平行、对照的临床试验,将78例受试对象随机分为对照组和治疗组;对照组30例常规使用异维A酸胶丸口服治疗,治疗组48例在上述治疗基础上联合百癣夏塔热片治疗,两组均外用克林霉素凝胶和0.025%迪维霜。疗程为6周,结束后观察疗效。结果：治疗组总有效率为89.58%,痊愈率为62.50%;对照组总有效率为66.67%,痊愈率为40.00%,两组疗效比较差异有统计学意义（P〈0.05）。结论：异维A酸胶丸联合百癣夏塔热片治疗中重度寻常型痤疮有较好的疗效,值得临床使用。     

清热暗疮胶囊联合夫西地酸乳膏治疗寻常型痤疮的疗效观察

目的观察清热暗疮胶囊联合夫西地酸乳膏治疗寻常型痤疮的疗效和不良反应。方法选取2013年2～9月于该科门诊就诊治疗的轻、中度寻常型痤疮患者115例,随机分为治疗组（58例）和对照组（57例）。治疗组采用口服清热暗疮胶囊（4片／次,每天3次）,同时外搽夫西地酸乳膏（每天2次）治疗;对照组采用口服四环素片（每次0．5g,每天2次）．同时外擦夫西地酸乳膏（每天2次）治疗。治疗8周后进行疗效评估。结果治疗组总有效率为91．38％（53／58）,高于对照组的75．44％（43／57）,差异有统计学意义（P〈0．05）。两组患者均有轻微不良反应,经对症处理后症状消失。结论清热暗疮胶囊联合夫西地酸乳膏治疗轻、中度寻常型痤疮疗效满意,无耐药性和严重的不良反应。     

Synthesis,Cytotoxicity and Antileishmanial Activity of Some N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines

We report herein the condensation of 4,7-dichloroquinoline (1) with tryptamine (2) and D-tryptophan methyl ester (3) . Hydrolysis of the methyl ester adduct (5) yielded the free acid (6) . The compounds were evaluated in vitro for activity against four different species of Leishmania promastigote forms and for cytotoxic activity against Kb and Vero cells. Compound (5) showed good activity against the Leishmania species tested, while all three compounds displayed moderate activity in both Kb and Vero cells.     

Efficacy of gut lavage,hemodialysis, and hemoperfusion in the therapy of paraquat or diquat intoxication

Clinical and in vitro investigations were carried out to test the efficacy of gut lavage, hemodialysis, and hemoperfusion in the treatment of poisoning with paraquat or diquat. In a patient suffering from diquat intoxication 130 times more diquat was removed by gut lavage 30 h after ingestion than was removed by complete aspiration of the gastric contents.Determination of in vitro clearances for paraquat and diquat by hemodialysis showed that, at serum concentrations of 1–2 ppm, such as are frequently encountered in poisoning in man, toxicologically relevant quantities of herbicide cannot be removed from the body. At a concentration of 20 ppm, on the other hand, hemodialysis proved to be effective, the clearance being 70 ml/min at a blood flow rate of 100 ml/min. The efficacy of hemoperfusion with coated activated charcoal was on the whole better. Especially at concentrations around 1–2 ppm, the clearance values for hemoperfusion were some 5–7 times higher than those for hemodialysis.In a patient suffering from paraquat poisoning, both hemodialysis as well as hemoperfusion were carried out. The in vitro results could be confirmed: At serum concentrations of paraquat less than 1 ppm no clearance could be obtained by hemodialysis while by hemoperfusion with activated charcoal quite high clearance values were measured and the serum level dropped down to zero.

---

Zusammenfassung Klinische Untersuchungen und Laboratoriumsversuche wurden durchgeführt, um die Wirksamkeit von Darmspülung, Hämodialyse und Hämoperfusion bei Paraquat- und Deiquat-Vergiftungen zu prüfen.Bei einem Patienten wurde 30 Std nach Deiquat-Aufnahme durch Darmspülung 130mal mehr Deiquat entfernt als durch vollständige Aspiration des Mageninhaltes. In vitro-Versuche ergaben, daß bei Blutserumkonzentrationen von 1–2 ppm, die bei Vergiftungen oft gemessen werden, durch Hämodialyse keine toxikologisch relevanten Paraquat- oder Deiquat-Mengen entfernt werden können. Dagegen erwies sich die Hämodialyse bei 20 ppm und einer Blutumlaufgeschwindigkeit von 100 ml/min mit einer Clearance von 70 ml/min als wirksam. Die Hämoperfusion mit beschicheter Aktivkohle war in diesen Versuchen aber eindeutig überlegen, denn insbesondere bei Konzentrationen um 1–2 ppm waren die Clearance-Werte 5–7mal höher als bei der Hämodialyse.Die in vitro-Ergebnisse wurden bei einem Patienten mit einer Paraquat-Vergiftung bestätigt: Bei Konzentrationen unter 1 ppm war die Hämodialyse wirkungslos, während durch Hämoperfusion relativ hohe Clearance-Werte erreicht wurden, so daß der Serumspiegel rasch unter die Nachweisgrenze abfiel.

     

In vitro studies on sterically stabilized liposomes (SL) as enzyme carriers in organophosphorus (OP) antagonism

This study describes a new approach for organophosphorous (OP) antidotal treatment by encapsulating an OP hydrolyzing enzyme, OPA anhydrolase (OPAA), within sterically stabilized liposomes. The recombinant OPAA enzyme was derived from Alteromonas strain JD6. It has broad substrate specificity to a wide range of OP compounds: DFP and the nerve agents, soman and sarin. Liposomes encapsulating OPAA (SL)* were made by mechanical dispersion method. Hydrolysis of DFP by (SL)* was measured by following an increase of fluoride ion concentration using a fluoride ion selective electrode. OPAA entrapped in the carrier liposomes rapidly hydrolyze DFP, with the rate of DFP hydrolysis directly proportional to the amount of (SL)* added to the solution. Liposomal carriers containing no enzyme did not hydrolyze DFP. The reaction was linear and the rate of hydrolysis was first order in the substrate. This enzyme carrier system serves as a biodegradable protective environment for the recombinant OP-metabolizing enzyme, OPAA, resulting in prolongation of enzymatic concentration in the body. These studies suggest that the protection of OP intoxication can be strikingly enhanced by adding OPAA encapsulated within (SL)* to pralidoxime and atropine.     

Lung disease and PKCs

The lung offers a rich opportunity for development of therapeutic strategies focused on isozymes of protein kinase C (PKCs). PKCs are important in many cellular responses in the lung, and existing therapies for pulmonary disorders are inadequate. The lung poses unique challenges as it interfaces with air and blood, contains a pulmonary and systemic circulation, and consists of many cell types. Key structures are bronchial and pulmonary vessels, branching airways, and distal air sacs defined by alveolar walls containing capillaries and interstitial space. The cellular composition of each vessel, airway, and alveolar wall is heterogeneous. Injurious environmental stimuli signal through PKCs and cause a variety of disorders. Edema formation and pulmonary hypertension (PHTN) result from derangements in endothelial, smooth muscle (SM), and/or adventitial fibroblast cell phenotype. Asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are characterized by distinctive pathological changes in airway epithelial, SM, and mucous-generating cells. Acute and chronic pneumonitis and fibrosis occur in the alveolar space and interstitium with type 2 pneumocytes and interstitial fibroblasts/myofibroblasts playing a prominent role. At each site, inflammatory, immune, and vascular progenitor cells contribute to the injury and repair process. Many strategies have been used to investigate PKCs in lung injury. Isolated organ preparations and whole animal studies are powerful approaches especially when genetically engineered mice are used. More analysis of PKC isozymes in normal and diseased human lung tissue and cells is needed to complement this work. Since opposing or counter-regulatory effects of selected PKCs in the same cell or tissue have been found, it may be desirable to target more than one PKC isozyme and potentially in different directions. Because multiple signaling pathways contribute to the key cellular responses important in lung biology, therapeutic strategies targeting PKCs may be more effective if combined with inhibitors of other pathways for additive or synergistic effect. Mechanisms that regulate PKC activity, including phosphorylation and interaction with isozyme-specific binding proteins, are also potential therapeutic targets. Key isotypes of PKC involved in lung pathophysiology are summarized and current and evolving therapeutic approaches to target them are identified.     

Steroidal sapogenin contents in some domestic plants

In order to find out the values of the steroid resources for the future use. the compositions and contents of steroidal sapogenins from 13 domestic plants have been investigated. As a result,Dioscorea nipponica, D. quinqueloba andSmilax china were found to have large amount of diosgenin. And pennogenin inTrillium kamtschaticum andParis verticillata, yuccagenin inAllium fistulosum, hecogenin inAgave americana and neochlorogenin inSolanum nigum were appeared to be major steroidal sapogenins.